United Drug is a healthcare services provider. The Company has four segments: Pharma Wholesale, Supply Chain Services, Medical and Scientific, and Contract Sales and Marketing Services.United Drug provides commercialisation solutions to international healthcare companies. We specialise in supply chain, packaging, sales and marketing, medical and regulatory services. We operate in five major international markets, and employ over 7,000 people around the world

http://www.united-drug.com/home/

Q3 trading statement

4 Aug Davy Research N/A Outperform
4 Aug Goodbody N/A Buy
4 Aug Numis 675.00 Add

10:30 27/10/2016
Broker Forecast - Liberum Capital issues a broker note on UDG Healthcare PLC
Liberum Capital today initiates coverage of UDG Healthcare PLC (LON:UDG) with a buy investment rating and price target of 750p. Story provided by StockMarketWire.com

Broker Forecast - Berenberg issues a broker note on UDG Healthcare PLC
BFN
Berenberg today reaffirms its buy investment rating on UDG Healthcare PLC (LON:UDG) and raised its price target to 720p (from 700p).

Story provided by StockMarketWire.com

Final results

Financial highlights (continuing Group only)
·    Diluted earnings per share1 (EPS) from continuing operations increased by 8% (9% on a constant currency basis).
·    Revenue growth of 3% to €943.1m. Underlying revenue2 up 7%.
·    Operating profit1 growth of 8% (9% on a constant currency basis) to €104.2 million.
·    Operating margin1 increased from 10.5% to 11.1%. Net operating margin3 increased from 12.2% to 12.6%.
·    Profit before tax1 up 10% (11% on a constant currency basis).
·    Proposed 5% increase in final dividend to 8.50c per share, yielding a full year dividend of 11.55c per share.
·    The Group has net cash of €128.3m at 30 September 2016.
·    Return on capital employed (ROCE) for 2016 was 13.7%, up from 13.5% in 2015.
 
Strategic & operating highlights
·    Disposal of the United Drug Supply Chain businesses and MASTA completed on 1 April 2016 resulting in a net profit on disposal of €132.1m.  
·     Completed the acquisition of Pegasus in April 2016, and STEM post year end. Both acquisitions are an excellent strategic fit for Ashfield, with good growth prospects and a higher margin profile.
·     Ashfield's operating profit increased by 7% (underlying growth2 of 9%), driven by positive underlying growth2 in both Ashfield Commercial & Clinical and Ashfield Communications.
·    Sharp's operating profit increased by 16% (underlying growth2 of 12%) driven by continued growth in the US commercial packaging business.
·   Sharp completed the build and fit out of its new packaging facility in Allentown, Pennsylvania increasing US commercial packaging capacity by approximately 30%. 
·     Aquilant's performance negatively impacted by adverse currency movements with underlying2 operating profit €0.2 million down.

13:20 15/12/2016
Broker Forecast - Jefferies International issues a broker note on UDG Healthcare PLC
Jefferies International today reaffirms its buy investment rating on UDG Healthcare PLC (LON:UDG) and raised its price target to 750p (from 745p). Story provided by StockMarketWire.com

1st Quarter Trading Update

RNS


RNS Number : 1585W

UDG Healthcare Public Limited Co.

07 February 2017




UDG HEALTHCARE PLC



FIRST QUARTER TRADING UPDATE



Good start to the year and full year guidance issued



7 February 2017:



UDG Healthcare plc ("the Group"), a leading international provider of healthcare services, issues the following trading update covering the period from 1 October to 31 December 2016. The company will hold its Annual General Meeting in Dublin at 12.00pm today.



Quarter to 31 December 2016



Group



The Group has made a good start to the financial year with operating profits for the quarter to 31 December 2016 well ahead of the same quarter last year. This performance has been driven by continued good underlying growth and the impact of acquisitions. As a result of the fall in the value of Sterling, reported profit growth was moderated by the translation of our Sterling profits into US Dollars.



Ashfield



Trading is well ahead of the same quarter last year, with good underlying growth supplemented by acquisitions. STEM was acquired in October 2016 and has performed in line with expectations.



Within the Ashfield Commercial & Clinical business, operating profit growth was strongest in the US, as the business ramps up activity on contract wins from 2016. The Ashfield communications business continues to perform well with underlying profit ahead of the same quarter last year.



Sharp



Divisional operating profits during the quarter were moderately ahead of a strong comparable quarter last year.



The Sharp US commercial packaging business continues to increase activity levels within its recently expanded facility in Allentown, Pennsylvania. The business also continues to increase its engagement with clients in preparation for the serialisation of prescription products from November 2017. Both factors are expected to have a more material benefit on performance in the second half of the year.



Sharp Europe remains focused on converting its improved business development pipeline into new business activity. This pipeline is mainly in the biotech focused Belgian facility.





Aquilant



Aquilant's underlying operating profits were in line with the same quarter last year.



Board Appointment



The Board is pleased to announce the appointment of Mr. Myles Lee as a non-executive director of the Company with effect from 1 April 2017. Mr. Lee was Group Chief Executive of CRH plc, a FTSE100 and Fortune 500 company, prior to retiring in December 2013.



Group Outlook & Development



With effect from 1 October 2016, the Group now reports its financial results in US Dollars.



Based on the Group's good trading performance during the first quarter of the financial year, the Group expects constant currency adjusted diluted earnings per share (EPS)1 for the year to 30 September 2017 to be between 13% and 16% ahead of last year's continuing Group EPS of US$ 31.8c (Euro: 28.6c).



The average FY16 exchange rates were US$1 = £0.704 and €0.90. Based on the current prevailing exchange rates, the Group is likely to face a foreign exchange headwind on the translation of Sterling profits in FY17.



The Group remains in a net cash position, leaving the business well positioned to continue its corporate development activities, which should serve to complement its continued underlying profit growth.



1 Before the amortisation of acquired intangible assets, transaction costs and exceptional items



Date for Interim Results



The Group will issue its interim results for the six months to 31 March 2017 on Tuesday 23 May 2017.

15:20 04/04/2017
Broker Forecast - Numis issues a broker note on UDG Healthcare PLC
Numis today downgrades its investment rating on UDG Healthcare PLC (LON:UDG) to hold (from add) and left its price target at 730p. Story provided by StockMarketWire.com
12:30 04/04/2017
Broker Forecast - Stifel issues a broker note on UDG Healthcare PLC
Stifel today reaffirms its hold investment rating on UDG Healthcare PLC (LON:UDG) and raised its price target to 650p (from 620p). Story provided by StockMarketWire.com

13:00 07/02/2018
Broker Forecast - N+1 Singer issues a broker note on UDG Healthcare PLC
N+1 Singer today reaffirms its hold investment rating on UDG Healthcare PLC (LON:UDG) and set its price target at 813p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
08:30 07/02/2018
Broker Forecast - Liberum Capital issues a broker note on UDG Healthcare PLC
Liberum Capital today upgrades its investment rating on UDG Healthcare PLC (LON:UDG) to buy (from hold) and left its price target at 884p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk

Notice of Interim Results
RNS
RNS Number : 6463M
UDG Healthcare Public Limited Co.
01 May 2018


1 May 2018
UDG Healthcare plc
Notice of Interim Results

UDG Healthcare plc ("the Group"), a leading international healthcare services provider, will issue its interim results for the half year ended 31 March 2018 at 07:00am (BST) on Tuesday 22 May 2018.

Interim report